HuLA immune Overview

  • Founded
  • 2017

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $3.68M

  • Investors
  • 2

HuLA immune General Information

Description

Operator of a drug development company intended to target and cure diseases. The company develops innovative drugs to cure autoimmune diseases and cancer based on microbiology and immunology research, enabling medical professionals to provide cures for rare diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1-4-1, Kasumigaseki, Chiyoda-ku
  • SENQ Kasumigaseki, 2nd Floor, Nichichi Building
  • Tokyo, 100-0013
  • Japan
+81 00-0000-0000

HuLA immune Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HuLA immune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 11-Mar-2020 $3.68M 00.000 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 12-Dec-2018 00.000 00.000 00.000 Completed Startup
To view HuLA immune’s complete valuation and funding history, request access »

HuLA immune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B Preferred 00,000 0000.00 0000.00 00 0000.00 00.000
Class A Preferred 00,000 0000.00 0000.00 00 0000.00 00.000
To view HuLA immune’s complete cap table history, request access »

HuLA immune Executive Team (2)

Name Title Board Seat Contact Info
Yasuhiro Shindo Ph.D Chief Executive Officer, Board Member & President
Tadashi Mori Ph.D Business Development Executive Officer & Board Member
To view HuLA immune’s complete executive team members history, request access »

HuLA immune Board Members (8)

Name Representing Role Since
Fumio Nishikaku Ph.D HuLA immune Board Member 000 0000
Mikihiko Shinozaki HuLA immune Board Member 000 0000
Tadashi Mori Ph.D HuLA immune Business Development Executive Officer & Board Member 000 0000
Yasuhiro Shindo Ph.D HuLA immune Chief Executive Officer, Board Member & President 000 0000
Yukoh Nakazaki HuLA immune Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

HuLA immune Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mitsubishi UFJ Capital Venture Capital Minority 000 0000 000000 0
Osaka University Venture Capital Venture Capital Minority 000 0000 000000 0
To view HuLA immune’s complete investors history, request access »